No I think this applies to down the road if one of these covid variants starts making some of the already approved MABs not be as effective that the FDA could combine to combat against new variants. I think this is good for CYDY it means if 100,000 patents start to get leronlimab and it’s working but could use a secondary potential helpful combo that they could do that but with leronlimab most likely won’t be needed as othe MABs might have trouble against the variants but not leronlimab as it isn’t lab made to fight specific covid-19 mutation.